期刊
CELLS
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cells10071802
关键词
stem cells; therapy; Alzheimer's disease; amyloid-beta; tau; inflammation; clinical symptoms
类别
资金
- Mitchell Foundation
- Alzheimer's Association
- Chilean Fund for Scientific and Technological Development (FONDECYT) [1140700]
Alzheimer's disease is the most common type of dementia in elderly population, characterized by progressive memory loss and cerebral atrophy. Induced pluripotent stem cells (iPSCs) have been suggested as a promising therapy to benefit patients at advanced clinical and pathological stages of AD.
Alzheimer's disease (AD) is the most common type of dementia in the elderly population. The disease is characterized by progressive memory loss, cerebral atrophy, extensive neuronal loss, synaptic alterations, brain inflammation, extracellular accumulation of amyloid-beta (A beta) plaques, and intracellular accumulation of hyper-phosphorylated tau (p-tau) protein. Many recent clinical trials have failed to show therapeutic benefit, likely because at the time in which patients exhibit clinical symptoms the brain is irreversibly damaged. In recent years, induced pluripotent stem cells (iPSCs) have been suggested as a promising cell therapy to recover brain functionality in neurodegenerative diseases such as AD. To evaluate the potential benefits of iPSCs on AD progression, we stereotaxically injected mouse iPSC-derived neural precursors (iPSC-NPCs) into the hippocampus of aged triple transgenic (3xTg-AD) mice harboring extensive pathological abnormalities typical of AD. Interestingly, iPSC-NPCs transplanted mice showed improved memory, synaptic plasticity, and reduced AD brain pathology, including a reduction of amyloid and tangles deposits. Our findings suggest that iPSC-NPCs might be a useful therapy that could produce benefit at the advanced clinical and pathological stages of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据